Browsing: KCAS

Immunogenicity Bz KCas image
0

Immunogenicity is the patient’s ability to generate antibodies, specific to the ‘dosed protein therapeutic’. In this blog post, Franklin Spriggs (KCAS; KS, USA) explains the importance of antibody-drug antibody assays and how data can be used towards safety profiles.

spotlight Image for BZ
0

KCAS, LLC optimized a primary and secondary stimulation assay of Peripheral Blood Mononuclear Cell (PBMC)
samples from a clinical trial in order to characterize the immune response to a multi-valent peptide vaccine. In partnership with our pharmaceutical sponsor, an agreed upon set of samples were tested by KCAS, LLC to optimize a culture method, culture time course, stimulation, and re-stimulation. These samples were also used to optimize surface and intracellular staining of the following panel: CD45, CD3 CD8, PD1, CCR7, IFNγ, TNFα, IL-2 and viability dye. Upon review of the initial optimized method, the full cohort of patient samples were cultured, treated, stained, and analyzed.

1 2